| Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).J Clin Oncol | PMID 35446628PMC9553390 | 2022-Oct-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX.Int J Cancer | PMID 35489024PMC9545440 | 2022-Oct-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.J Clin Oncol | PMID 35584336PMC9553388 | 2022-Oct-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Follow-up Schedule for Patients With Sentinel Node-negative Cutaneous Melanoma (The MELFO Study): An International Phase III Randomized Clinical Trial.Ann Surg | PMID 35866644无 PMCID | 2022-Oct-01 | 0.90 | The study is a Phase III randomized trial in human oncology with a primary time-to-event endpoint (DFS), but the intervention is a follow-up strategy, not a drug-containing regimen as required for inclusion. | 待处理 |
| Ultrasound-guided selective trunk block: Evaluation of ipsilateral sensorimotor block dynamics, hemidiaphragmatic function and efficacy for upper extremity surgery. A single-centre cohort study.Eur J Anaesthesiol | PMID 35950709无 PMCID | 2022-Oct-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.JAMA Oncol | PMID 35980649PMC9389440 | 2022-Oct-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial.Lancet | PMID 36099926无 PMCID | 2022-Oct-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study.Br J Ophthalmol | PMID 34001667PMC9510409 | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2.J Eur Acad Dermatol Venereol | PMID 35460287PMC9545614 | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of N-acetyl-GED-0507-34-LEVO gel in patients with moderate-to severe facial acne vulgaris: a phase IIb randomized double-blind, vehicle-controlled trial.Br J Dermatol | PMID 35553043PMC9796277 | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized clinical trial of BCG vaccine in patients with convalescent COVID-19: Clinical evolution, adverse events, and humoral immune response.J Intern Med | PMID 35599154PMC9347570 | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial.Diabetes Obes Metab | PMID 35670659PMC9546064 | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The role of plasma exosomal lnc-SNAPC5-3:4 in monitoring the efficacy of anlotinib in the treatment of advanced non-small cell lung cancer.J Cancer Res Clin Oncol | PMID 35672525PMC11800937 | 2022-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center, randomized, double-blind, phase III clinical trial.Clin Rheumatol | PMID 35676450无 PMCID | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Respir Med | PMID 35688164PMC9173721 | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials.J Am Acad Dermatol | PMID 35714786无 PMCID | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| [Multimodality treatment in high-risk and very high-risk prostate cancer: outcomes from international phase III randomized controlled trials].Strahlenther Onkol | PMID 35732920无 PMCID | 2022-Oct | 0.85 | While the record meets criteria for oncology, human, randomized, Phase III, and original result, it lacks explicit evidence of a drug intervention and a time-to-event efficacy endpoint from the provided metadata. Therefore, it is not eligible. | 待处理 |
| A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough.Allergol Int | PMID 35752582无 PMCID | 2022-Oct | 0.95 | The study is a randomized, double-blind, Phase III trial evaluating the safety and efficacy of gefapixant for chronic cough (refractory or unexplained), which is a non-oncological condition. While it meets criteria for human, randomized, Phase III, drug intervention, and original results, it is excluded because it is not an oncology study and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The endpoints reported are safety, tolerability, and quality of life, not the required time-to-event efficacy outcomes. | 待处理 |
| Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study.Bone Marrow Transplant | PMID 35768571PMC9532240 | 2022-Oct | 0.85 | The record is from a randomized Phase III trial in oncology (multiple myeloma) and includes a drug intervention (cyclophosphamide). However, the specific report is an exploratory, post-hoc analysis of genetic variants in relation to patient-reported quality of life and pain, not a primary efficacy result. It lacks any primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, Kaplan-Meier, HR). | 待处理 |
| Early versus delayed treatment with glatiramer acetate: Analysis of up to 27 years of continuous follow-up in a US open-label extension study.Mult Scler | PMID 35768939PMC9442630 | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of intravenous OPC-61815 compared with oral tolvaptan in patients with congestive heart failure.ESC Heart Fail | PMID 35794067PMC9715865 | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial.Lancet Respir Med | PMID 35817072PMC9270059 | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact on xerostomia for nasopharyngeal carcinoma patients treated with superficial parotid lobe-sparing intensity-modulated radiation therapy (SPLS-IMRT): A prospective phase II randomized controlled study.Radiother Oncol | PMID 35817320无 PMCID | 2022-Oct | 0.95 | The study is a Phase II randomized trial in oncology with human patients and includes time-to-event efficacy endpoints (LRRFS, DMFS, OS). However, it is ineligible because it is Phase II (not Phase III/IIIb) and the intervention is a radiation technique (SPLS-IMRT vs C-IMRT), which is a non-drug intervention. The primary endpoint is xerostomia incidence, not a time-to-event efficacy endpoint. The deterministic review correctly flagged insufficient drug intervention evidence. | 待处理 |
| Re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial.Eur Urol | PMID 35902289无 PMCID | 2022-Oct | 0.55 | The record is a Phase III randomized trial with a time-to-event endpoint (DFS) in human prostate cancer. However, the abstract is empty and the provided metadata (including the deterministic review's 'drug_intervention: false' signal) does not contain explicit evidence that a systemic drug intervention was part of the trial's control or experimental arms. The trial involves 'Androgen Deprivation' which could be a drug intervention (e.g., androgen antagonists), but this is not explicitly confirmed as a drug-containing intervention in the provided data. Therefore, eligibility cannot be confirmed. | 待处理 |
| EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.Eur J Cancer | PMID 35922251无 PMCID | 2022-Oct | 0.95 | This is a primary report of a Phase III randomized trial in oncology with a drug intervention, but the explicitly reported primary/key secondary endpoints are patient-reported quality-of-life and functioning outcomes (EORTC QLQ-C30 scales), not time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR analysis. The 'time to definitive deterioration' mentioned is a time-to-event analysis of patient-reported outcomes, not a traditional oncological efficacy endpoint. | 待处理 |
| Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study.Lancet Respir Med | PMID 35926542无 PMCID | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study.Calcif Tissue Int | PMID 35927518无 PMCID | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Assessment of Two Formulations of Triptorelin in Chinese Patients with Endometriosis: A Phase 3, Randomized Controlled Trial.Adv Ther | PMID 35947347PMC9464738 | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.Leukemia | PMID 35963941无 PMCID | 2022-Oct | 0.45 | The record is a secondary biomarker analysis from a Phase III randomized trial. While it meets criteria for oncology, human, randomized, phase3, drug intervention, and is an original result, it lacks the required time-to-event efficacy endpoint (e.g., OS, PFS) and associated statistics (Kaplan-Meier, HR) for the primary/key secondary endpoint. The deterministic review correctly identified the absence of a time-to-event signal. | 待处理 |
| Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitis.Clin Transl Sci | PMID 35986664PMC9579381 | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections.Int J Infect Dis | PMID 35987467无 PMCID | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer.ESMO Open | PMID 35994789PMC9588898 | 2022-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar.Mult Scler Relat Disord | PMID 36007339无 PMCID | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of 1PC111, a Fixed-dose Combination of Pitavastatin and Ezetimibe, Versus Pitavastatin or Ezetimibe Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia or Mixed Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase III Study.Clin Ther | PMID 36030106无 PMCID | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| An exposure-response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis.CPT Pharmacometrics Syst Pharmacol | PMID 36047474PMC9574745 | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Survival outcomes in a prospective randomized multicenter Phase III trial comparing patients undergoing anatomical segmentectomy versus standard lobectomy for non-small cell lung cancer up to 2 cm.Lung Cancer | PMID 36058174无 PMCID | 2022-Oct | 0.90 | The study is a Phase III randomized trial with primary time-to-event endpoints (OS, DFS) for human oncology, but it compares surgical procedures and does not include a drug-containing intervention as required by the criteria. | 待处理 |
| Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.Eur J Cancer | PMID 36067615无 PMCID | 2022-Oct | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.Lancet Oncol | PMID 36075260无 PMCID | 2022-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.Drugs Aging | PMID 36098936PMC9553778 | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.Lancet Oncol | PMID 36108662无 PMCID | 2022-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Tolerability of Ezetimibe/Atorvastatin Fixed-dose Combination Versus Atorvastatin Monotherapy in Hypercholesterolemia: A Phase III, Randomized, Active-controlled Study in Chinese Patients.Clin Ther | PMID 36182594无 PMCID | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial.Headache | PMID 36239038PMC9827820 | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Multicenter, Randomized, Double-blind, Active-controlled, Factorial Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hypercholesterolemia.Clin Ther | PMID 36241463无 PMCID | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of Actovegin in the treatment of intermittent claudication: results of an international, multicenter, placebo-controlled, randomized, phase IIIb clinical trial (APOLLO).Int Angiol | PMID 36264097无 PMCID | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open-label extension.Headache | PMID 36286602无 PMCID | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.Drugs | PMID 36287379PMC9607700 | 2022-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT.Health Technol Assess | PMID 36300825PMC9639219 | 2022-Oct | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk.Clin Infect Dis | PMID 35165682PMC9525090 | 2022-Sep-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies.Clin Infect Dis | PMID 35148378PMC9522395 | 2022-Sep-29 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.JAMA | PMID 36166026PMC9516323 | 2022-Sep-27 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |